18 Oct 2023

HKSTP and WuXi XDC Join Forces to Promote Development of Bioconjugate Drug Industry in Hong Kong

20231018_v2
Hong Kong Science and Technology Parks Corporation (HKSTP) and WuXi XDC, a leading global contract research, development and manufacturing organisation (CRDMO) specialised in the bioconjugate market, signed a collaboration framework agreement to jointly advance the establishment of a CRDMO value chain in Hong Kong.

Key Takeaways

  • HKSTP and WuXi XDC signed a collaboration framework agreement to jointly promote the establishment of a contract research, development and manufacturing organisation (CRDMO) value chain in Hong Kong.
  • HKSTP Park companies will leverage WuXi XDC’s one-stop service platform to develop Antibody Drug Conjugate (ADC) and other bioconjugates.
  • WuXi XDC will support the advancement of the bioconjugation industry in Hong Kong by providing consultation and training to local enterprises.